MOL.LSE Molecule Group plc
- Market cap
- GBX 53.5M
- P/E
- -
- P/B
- 1.23x
- ROE
- -12.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is MOL.LSE undervalued?
Graham numberThe Graham number of Molecule Group plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Molecule Group plc fundamental analysis
No fundamental analysis for Molecule Group plc yet.
Molecule Group plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Molecule Group plc
Molecule Group plc operates as an investment company that focuses on acquiring companies or businesses in the ePharmacy market. The company was formerly known as Vulcan Two Group Plc and changed its name to Molecule Group plc in October 2026. The company was incorporated in 2025 and is based in London, United Kingdom.
Full company profileMolecule Group plc financial statements
Molecule Group plc annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -23.0K | -74.5K | -25.3K | -1.30M |
| EBITDA | -23.0K | -74.5K | -25.3K | -1.30M |
| Net Income | -22.7K | -74.5K | -25.3K | -1.22M |
| EPS | 0.00 | -0.01 | 0.00 | -0.18 |
| Balance Sheet | ||||
| Total Assets | 67.3K | 10.9K | 536.00 | 10.0M |
| Total Liabilities | 90.0K | 108K | 123K | 365K |
| Shareholders' Equity | -22.7K | -97.2K | -123K | 9.68M |
| Cash & Short-term Investments | 63.5K | 10.5K | 99.00 | 9.55M |
| Cash Flow | ||||
| Operating Cash Flow | -26.8K | -71.0K | -25.4B | -1.39T |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 2.83B |
| Free Cash Flow | -26.8K | -71.0K | -25.4B | -1.39T |
| Ratios | ||||
| ROE | - | - | - | -12.6% |
| ROA | -33.7% | -682.0% | -4,728.0% | -12.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Molecule Group plc dividends
Molecule Group plc has not paid dividends in the last 4 fiscal years.
Who owns Molecule Group plc
- Insiders 7.63%
- Institutions 92.37%
- Public & others 0.00%
- Shares outstanding 27.3M
- Free float 13.6M
Molecule Group plc company profile
- Company name
- Molecule Group plc
- Ticker
- MOL.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
- Employees
- 6
- Fiscal year end
- December
- Address
- 201 Temple Chambers, London, United Kingdom, EC4Y 0DT
- Website
- vulcantwo.com
About Molecule Group plc
Molecule Group plc operates as an investment company that focuses on acquiring companies or businesses in the ePharmacy market. The company was formerly known as Vulcan Two Group Plc and changed its name to Molecule Group plc in October 2026. The company was incorporated in 2025 and is based in London, United Kingdom.
Molecule Group plc management
4- Mr. Michael Benjamin KraftmanCEO & Executive Director · born 1957
- Mr. Brendan Celestine O'BrienCOO & Director · born 1968
- Mr. Keith Butcher ACA, BscChief Financial Officer & Director · born 1962
- Mr. Declan LismoreChief Pharmacy Officer